To overcome these problems, 2nd generation FLT3 inhibitors with selective FLT3 inhibitory activity such as gilteritinib, quizartinib, and crenolanib have been developed46,47, and gilteritinib was recently approved for relapsed/refractory adult AML patients with mutated FLT349. The gene discussed is FLT3; the disease is acute myeloid leukemia.